Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
14 Vues
• 07/18/23
0
0
Intégrer
administrator
Les abonnés
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
Montre plus
Commentaires de Facebook
SORT BY-
Meilleures Commentaires
-
Derniers Commentaires